X

Trial Profile

A phase II study assessing oral therapy Xanamem in boys with fragile X syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UE 2343 (Primary)
Indications Fragile X syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms XanaFX
Sponsors Actinogen Medical

Most Recent Events

23 Jun 2021 According to an Actinogen Medical media release, company plans to file the full IND submission in Q3 21 base on this study and has received written supportive US FDA advice in response to its Pre-Investigational New Drug Application (Pre-IND) submission..
23 Jun 2021 According to an Actinogen Medical media release, company expected to commence in 4Q CY21.
30 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com